ClinicalTrials.gg
CompletedNCT04630067Updated Oct 20, 2022

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

A Phase 1 interventional study of AZD3427 and Placebo in Heart Failure, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-20.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 64 studies in Heart Failure by AstraZeneca — 5 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Enrollment
23rd of 39
105 · median 160
Started
2020
with 4 others
Phase 1
13 of 64
none open now
Registered
36th of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2020, is one of 13 in phase 1, and was the 36th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of AZD3427 in patients with heart failure (HF).

Read the detailed description

This is a multi-center single and multiple ascending dose study (SAD and MAD).

Part A (SAD) will include 7 cohorts (8 healthy volunteers in each cohort) and will randomize to AZD3427 or placebo, in a 6:2 ratio. One cohort will entirely include participants of Japanese descent.

Part B (MAD) will include 6 cohorts (8 heart failure patients in each cohort) and will randomize to AZD3427 or placebo in a 6:2 ratio. Of these, 3 cohorts will contain participants with heart failure with reduced ejection fraction [HFrEF] and the other 3 cohorts will comprise of participants with heart failure with HF with ejection fraction (EF) ≥ 41%. There will be a maximum screening period of 27 days. Participants in part A and B will undergo study drug administration on Day 1. In addition, participants in part B will return for 4 additional doses on Days 8, 15, 22, and 29. Participants will be followed for at least 50 days after the last dose of study drug.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure with reduced ejection fraction
  • Heart failure with ejection fraction of ≥ 41%
  • AZD3427
  • First-time-in-human
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part A will include healthy men and non-pregnant, non-lactating females of non- with a (BMI) of 18-30 kg/m\^2 and a weight of 55-100 kg. One cohort will require participants be of Japanese descent
  • Part B will include men and non-pregnant, non-lactating females of non-childbearing potential
  • Participants have a BMI of 18-40 kg/m\^2 and a weight of 55-136 kg
  • Participants with a diagnosis of stage C HF (NYHA) Class I-III on stable medical therapy for at least 12 weeks
  • Participants with diagnosis of HFrEF will be defined as those with EF ≤ 40% and HF with EF ≥ 41%
  • Participants either with N-terminal prohormone of brain natriuretic peptide (NT-proBNP) > 125 pg/mL or BNP > 35 pg/mL (46)

Exclusion criteria

Exclusion Criteria:

Both Part A and Part B will exclude participants with any of the following:

  • Any illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study drug or planned surgical procedure before study completion
  • History of vascular and left ventricular aneurysms or prior dissections
  • Any history of joint hypermobility, Marfan's syndrome, or any connective tissue disorder
  • Clinical signs and symptoms consistent with Coronavirus disease-19 or confirmed infection within the last 4 weeks
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity injection devices or to drugs with a similar chemical structure or class to AZD3427 or any component of AZD3427

In addition, Part A will exclude participants with any of the following:

  • (ALT) > (ULN)
  • Aspartate Aminotransferase (AST) > ULN
  • Total > ULN (unless due to Gilbert's syndrome)
  • Creatinine > ULN
  • White blood cell (WBC) count \< Lower limit of normal (LLN)
  • \< LLN
  • Prolonged > 450 m
  • Shortened QTcF \< 340 ms
  • Family history of long QT syndrome
  • PR (PQ) interval shortening \< 120 ms (PR > 110 ms but \< 120 ms is acceptable if there is no evidence of ventricular pre-excitation)
  • PR (PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third-degree atrioventricular (AV) block, or AV dissociation
  • Persistent or intermittent complete bundle branch block, incomplete bundle branch block, or intraventricular conduction delay with QRS > 110 ms. Participants with QRS > 110 ms but \< 115 ms are acceptable if there is no evidence of eg, ventricular hypertrophy or pre-excitation

In addition, Part B will exclude participants with any of the following:

  • Atrial fibrillation or flutter occurring in the past year
  • Clinically significant ventricular arrhythmias under treatment
  • High-degree AV block II-III or sinus node dysfunction
  • Implanted permanent pacemaker or implantable cardioverter defibrillator for which the participant is pacing-dependent
  • Severe right-sided valvular heart disease; severe mitral regurgitation; moderate or severe mitral stenosis, severe aortic regurgitation and mild, moderate or severe aortic stenosis
  • Other conditions where vasodilatory therapy may be (hypertrophic obstructive cardiomyopathy, and restrictive cardiomyopathy)
  • Congenital heart disease
  • HF Class IV
  • Occurrence in the last 6 months of acute coronary syndrome, percutaneous coronary intervention, cerebrovascular accident or , HF hospitalization; history or suspicion of cardiac amyloidosis
  • ALT > 1.5 × ULN
  • AST > 1.5 × ULN
  • Total bilirubin > ULN (unless due to Gilbert's syndrome)
  • Impaired renal function, defined as \< 30 mL/min/1.73m\^2 assessed by the Chronic Kidney Disease Epidemiology Collaboration equation
  • WBC \< LLN
  • Hemoglobin \< 10g/L
  • PR (PQ) interval prolongation (> 220 ms)
  • Participants with persistent BBB and QRS ( interval measured from the onset of the QRS complex to the J point) duration > 130 ms. Participants with intraventricular conduction delay and QRS duration \< 130 ms
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    AZD3427: Cohort 1a

    Participants will receive single SC dose A of AZD3427 on Day 1.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 2a

    Participants will receive single SC dose B of AZD3427 on Day 1.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 3a

    Participants will receive single SC dose C of AZD3427 on Day 1.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 4a

    Participants will receive single SC dose D of AZD3427 on Day 1.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 5a

    Participants will receive single IV dose E of AZD3427 on Day 1.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 6a

    Participants of Japanese descent will receive single SC dose anticipated equal to the highest dose of AZD3427 in the global cohorts on Day 1.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 7a

    Participants will receive single SC dose F of AZD3427 on Day 1

    Drug: AZD3427

  • Placebo comparator
    Part A: Placebo

    Participants will receive single SC or IV dose of placebo matched to AZD3427 on Day 1.

    Drug: Placebo

  • Experimental
    AZD3427: Cohort 1b

    Participants with HFrEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 2b

    Participants with HF with EF ≥ 41% will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 3b

    Participants with HFrEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 4b

    Participants with HF with EF ≥ 41% will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 5b

    Participants with HFrEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.

    Drug: AZD3427

  • Experimental
    AZD3427: Cohort 6b

    Participants with HF with EF ≥ 41% will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.

    Drug: AZD3427

  • Placebo comparator
    Part B: Placebo

    Participants with HFrEF or HF with EF ≥ 41% will receive SC dose of placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.

    Drug: Placebo

Interventions

  • Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

  • DrugPlacebo

    Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events and Serious Adverse Events

    Assessment of the safety and tolerability of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 until Day 50 or Early termination visit (E/T); Part B: Day 1 until Day 78 or E/T

Secondary outcomes

  1. Maximum Observed Serum (peak) Drug Concentration (Cmax) of AZD3427

    Evaluation of the PK of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose, and 10 minutes [only for cohort 5a], 4hrs and 12hrs post-dose, and days 2, 3, 5, 8, 15, 29, and Day 50 or E/T ; Part B: Day 1 (Pre-dose and post-dose), days 8, 15, 22, and 29 (pre-dose); and days 2, 3, 32, 57, 71 and 78 or E/T

  2. Area Under the Serum Concentration-time Curve from Zero to the Last Quantifiable Concentration (AUClast)

    Evaluation of the PK of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose, and 10 minutes [only for cohort 5a], 4hrs and 12hrs post-dose, and days 2, 3, 5, 8, 15, 29, and Day 50 or E/T ; Part B: Day 1 (Pre-dose and post-dose), days 8, 15, 22, and 29 (pre-dose); and days 2, 3, 32, 57, 71 and 78 or E/T

  3. Area Under Serum Concentration-time Curve From Zero to Infinity (AUCinf)

    Evaluation of the PK of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose, and 10 minutes [only for cohort 5a], 4hrs and 12hrs post-dose, and days 2, 3, 5, 8, 15, 29, and Day 50 or E/T ; Part B: Day 1 (Pre-dose and post-dose), days 8, 15, 22, and 29 (pre-dose); and days 2, 3, 32, 57, 71 and 78 or E/T

  4. Area Under the Serum Concentration-time Curve from Zero to 168 Hours Post-dose Administration (AUC0-168)

    Evaluation of the PK of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose, and 10 minutes [only for cohort 5a], 4hrs and 12hrs post-dose, and days 2, 3, 5, 8, 15, 29, and Day 50 or E/T ; Part B: Day 1 (Pre-dose and post-dose), days 8, 15, 22, and 29 (pre-dose); and days 2, 3, 32, 57, 71 and 78 or E/T

  5. Time to Reach Peak or Maximum Observed Concentration or Response Following Drug Administration (tmax)

    Evaluation of the PK of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose, and 10 minutes [only for cohort 5a], 4hrs and 12hrs post-dose, and days 2, 3, 5, 8, 15, 29, and Day 50 or E/T ; Part B: Day 1 (Pre-dose and post-dose), days 8, 15, 22, and 29 (pre-dose); and days 2, 3, 32, 57, 71 and 78 or E/T

  6. Half-life Associated with Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)

    Evaluation of the PK of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose, and 10 minutes [only for cohort 5a], 4hrs and 12hrs post-dose, and days 2, 3, 5, 8, 15, 29, and Day 50 or E/T ; Part B: Day 1 (Pre-dose and post-dose), days 8, 15, 22, and 29 (pre-dose); and days 2, 3, 32, 57, 71 and 78 or E/T

  7. Number of Participants Testing Positive for the Presence of Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) to AZD3427

    Evaluation of the immunogenicity of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose), Days 15, 29, and 50 or E/T; Part B: Days 1, 15, 29 (Pre-dose), Days 57 and 78 or E/T

  8. Evaluation of Positive Anti-drug Antibodies Titer

    Evaluation of the immunogenicity of single and multiple ascending doses of AZD3427.

    Time frame: Part A: Day 1 (pre-dose), Days 15, 29, and 50 or E/T; Part B: Days 1, 15, 29 (Pre-dose), Days 57 and 78 or E/T

07

Study locations

10 sites
  • Research Site
    Little Rock, Arkansas 72204, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Doral, Florida 33166, United States
  • Research Site
    Hallandale Beach, Florida 33009, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Owensboro, Kentucky 42303, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Sep 2022, 21 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 21 months is above that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2020
First posted
Nov 16, 2020
StartActual
Nov 17, 2020
Primary completionActual
Sep 14, 2022
CompletionActual
Sep 14, 2022
Last update
Oct 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04630067
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
Nov 17, 2020
Primary completion
Sep 14, 2022
Completion
Sep 14, 2022
Last update
Oct 20, 2022

Study contacts

Ronald Goldwater, MD
principal investigator · Parexel Early Phase Clinical Unit (Baltimore), Harbor Hospital, 3001 S. Hanover St., Baltimore, MD 21225, United States of America (USA)
David Lanfear, MD
principal investigator · Henry Ford Hospital, USA, MI

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD3427

Start the discussion